drugset / Trial / NCT06052852
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
Timeline
- Start
- 2023-10-11
- Primary completion
- 2025-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BDC-3042 | Monoclonal antibody | — | — |
| Subject | Cemiplimab | Monoclonal antibody | — | — |